Zhejiang Xinguang Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2019
October 27, 2019 at 04:06 am
Share
Zhejiang Xinguang Pharmaceutical Co., Ltd. announced earnings results for the nine months ended September 30, 2019. For the nine months, the company announced sales was CNY 213.143 million compared to CNY 204.001 million a year ago. Operating income was CNY 81.763 million compared to CNY 77.646 million a year ago. Net income was CNY 69.251 million compared to CNY 66.236 million a year ago. Basic earnings per share from continuing operations was CNY 0.4328 compared to CNY 0.414 a year ago.
Zhejiang Xinguang Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, production and sales of Chinese patent medicines, chemical medicines and health foods. The Company's main products are Huangqishengmaiyin, Shenjindan Capsules, American Ginseng Oral Liquid and other products. The treatment scope is mainly cardiovascular and cerebrovascular diseases, trauma diseases, and covers respiratory system, digestive system, urinary system, pediatric diseases and improving immunity. The Company operates its businesses mainly in domestic markets, with Zhejiang Province as its major market.